

O I P E J C 1 7 7
 FEB 1 3 2002
 PATENT & TRADEMARK OFFICE
 Krz

FEB 15 2002

TECH CENTER 1600/2900

Application No.: 09/840,243

)
)
)
)
) **Group Art Unit: 1623**

Filed: April 24, 2001

) Examiner: Unassigned

For: NEW TRANSCRIPTION FACTOR)
OF MHC CLASS II GENES, SUB-)
STANCES CAPABLE OF INHIBITING)
THIS NEW TRANSCRIPTION)
FACTOR AND MEDICAL USES)
OF THESE SUBSTANCES)

BOX: SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


I, Susan M. Dadio, declare as follows:

1. That, in compliance with 37 C.F.R. § 1.821(f), the content of the second substitute paper copy of the Sequence Listing included in the concurrently filed Response to Notice to Comply with Sequence Listing Requirements and Preliminary Amendment for incorporation into the specification and the content of the second substitute computer readable copy of the Sequence Listing filed concurrently herewith, are the same.
2. That the submission, filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued.

February 13, 2002

Date



Susan M. Dadio
Reg. No. 40,373